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OBJECTIVE:  To  report  a case  of malignant  chondroid  syringoma,  a rare  skin  tumor  at  Joliot  Curie  Cancer
Institute  in  Dakar.
RESULTS: We  report  a case of  malignant  chondroid  syringoma  of the  deltoid  and  axilla  in a  53  year  old
patient.  Malignant  chondroid  syringoma  is  an  extremely  rare tumor  of the  sweat  glands.  It is  included  invailable online 23 June 2016
eywords:
alignant
yringoma
pithelial
myoepithelial  tumors  of the  skin.  It has  an  epithelial  component  with  eccrin  or apocrin  differentiation,
and  myoepithelial  component.  It  preferentially  seat  at the  extremities.  We  report  an  unusual  case  with
deltoid presentation  and  axillary  mass  masqueriding  as  metastatic  lymph  node.  Surgery  is  the main
treatment.  It has a  poor  prognosis.
© 2016  The  Author(s).  Published  by  Elsevier  Ltd  on behalf  of IJS  Publishing  Group  Ltd.  This  is  an  open
he  CCyoepithelial access  article  under  t
. Introduction
Malignant chondroid syringoma (MCS) is a tumor of sweat
lands that preferentially interested ends [1]. Unlike chondroid
yringoma which is a rare benign tumor of the skin appendages
ith very slow growing [2], MCS, also called malignant mixed
umor of the skin, is extremely rare [3] with poor prognosis. We
eport a case of malignant chondroid syringoma of the axillary
egion in our practice at Joliot Curie Cancer Center in Dakar.
. Case presentation
It was about a 53 year old patient who consulted for a mass of
he right deltoid area. Eighteen months before he noticed a pain-
ess nodule of the right shoulder which has risen steadily in volume
ith the appearance of axillary nodule. The examination revealed a
0 cm mass at the right deltoid region with edema and skin involve-
ent (Fig. S1). MRI  of the right shoulder objectiﬁed a necrotic tumor
t the lower back part of the deltoid and triceps inﬁltrating the
nvasive axillary region with axillary malignant lymph node. Micro-
copic examination showed in the deltoid lesion, dermis covered
y normal skin and occupied by a dense ﬁbro-collagen tissue, and
ew inﬂammatory, polymorphic, predominantly perivascular cells
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making a scar. At the axillary mass initially considered as a lymph
node, microscopic examination revealed tumor fragments without
lymphoid tissue. It showed extended necrosis, bays and cords with
cells sometimes small, compact, round nuclei, dense chromatin,
to scanty cytoplasm, poorly deﬁned, sometimes trabecular with
larger cells, eosinophilic cytoplasm fairly abundant, forming acinar
and alveolar provisions. Sometimes they took a signet ring appear-
ance in vacuolated cytoplasm, or plasmacytoid eosinophils. Spans
and cords were separated by a myxoid stroma with many stellate
cells, myoepithelial types with slightly irregular nuclei. Moreover,
there was many peri-nervous and muscle tissue inﬁltration. Some
isolated cells were PAS positive. In summary there was a biphasic
tumor tissue cell, epithelial and myoepithelial evoking carcinoma
or malignant mixed tumor. At Immunohistochemistry, the epithe-
lial cells expressed cytokeratin gaits AE1/AE3, PS100 and P63. The
spindle-shaped and stellate cells expressed actin and rarely PS100.
All in favor of a malignant chondroid syringoma. As the patient was
opposed to a radical surgical treatment, an adryamycin-cisplatin
based chemotherapy was instituted. The evolution was marked
by growth with increased volume of the lesions that had become
painful. Death occurred 8 months after diagnosis.
3. Discussion
MCS  was ﬁrst described by Hirsch and Helwig in 1961 [4]. The
term of “atypical mixed tumor of the skin” is used to describe
tumors characterized by histological stigma of malignancy, recur-
rence, local invasion and satellite tumor nodules without proven
metastases [5].
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Epidemiologically, malignant chondroid syringomas have a
emale predilection while their benign counterparts are more com-
on  in men. Clinically, they are characterized by a faster growth
nd a size signiﬁcantly greater than that of benign mixed tumors
6].
There is no evidence of a speciﬁc risk factor. Trauma has been
uggested as a possible predisposing factor for the development of
oth malignant and benign chondroid syringoma [1].
Unlike the benign variety that preferentially seat at the head
nd neck, malignant chondroid syringoma seat preferentially in
xtremities and trunk [1,5].
Malignant chondroid syringoma can appear de novo or more
arely be developped from a cartilaginous syringoma [2]. In fact,
arely however, a chondroid syringoma after many years of evolu-
ion, can undergo malignant transformation and be metastatic.
The pathological diagnosis of adnexal tumors of the skin is
ifﬁcult. It is made on material of ﬁne needle aspiration, biopsy
r surgery [6]. It is related ﬁrstly to the wide variety of tumors
nd their variants and on the other hand to the differentiation
f adnexal lines of frequency in the same tumor [3]. The chon-
roid syringomas are included in myoepithelial skin tumors. The
hondroid syringoma has an epithelial component with eccrine
r apocrine differentiation, and myoepithelial component of vary-
ng importance with stellate myoepithelial cells or plasmacytoid
hondro-myxoid in a matrix [1,5]. These characteristics were found
uring pathological examination of our patient. The immunos-
aining showed a positivity of epithelial markers (cytokeratin),
pithelial structures, vimentin, PS100, actin and calponin for both
mooth muscle and myoepithelial cells. It was a signiﬁcant contri-
ution for our patient. Basal cells and adenoid cystic carcinomas
eem to be strong differential diagnosis [7].
There is no evidence of the effectiveness of chemotherapy
nd radiotherapy in the treatment of SCM. Some authors used
hemotherapy based on 5-FU, prednisone and Cytoxan and radio-
herapy [5]. Early wide excision and margins appears to be the most
eliable treatment [2]. For other authors adjuvant radiotherapy is
seful to decrease recurrence [8]. Chemotherapy made in the case
f our patient, based on adryamycin and cisplatin, did not prevent
rogression and death.
The clinical course of MCS  is deemed unpredictable. The spread
an be lymphatic or blood-borne [5]. The two most common sites
or distant metastases are lungs and bones [9].
. Conclusion
The MCS  is an extremely rare malignant tumor of sweat
lands. Pathological examination is the key of diagnosis, showing
n epithelial component, eccrine or apocrine differentiation and
yoepithelial component of varying importance. The immunos-
aining is very helpful because there is a positivity for epithelial
nd myoepithelial markers. For the treatment, an early and
arge excision with clear margins is the most reliable treatment.
hemotherapy and radiotherapy are not effective. The prognosis
epends on early diagnosis and complete resection and remains
oor.
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